Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 4,000 shares at $310.08 ($1.3M) on 2026-02-13, disclosed to the SEC on 2026-02-17.
Scheduled sale ($1.3M) by CSO & EVP, Head of Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $310.08 | 1,959 | $607K | 47.3% |
| 2 | $331.96 | 2,041 | $678K | 52.7% |
| Total | $321.24 avg | 4,000 | $1.3M | 100% |
| Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $2.1M | — | Filing → |